L Hayley Burgess
Overview
Explore the profile of L Hayley Burgess including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gohil S, Septimus E, Kleinman K, Varma N, Avery T, Heim L, et al.
JAMA
. 2024 Apr;
331(23):2007-2017.
PMID: 38639729
Importance: Pneumonia is the most common infection requiring hospitalization and is a major reason for overuse of extended-spectrum antibiotics. Despite low risk of multidrug-resistant organism (MDRO) infection, clinical uncertainty often...
2.
Gohil S, Septimus E, Kleinman K, Varma N, Avery T, Heim L, et al.
JAMA
. 2024 Apr;
331(23):2018-2028.
PMID: 38639723
Importance: Urinary tract infection (UTI) is the second most common infection leading to hospitalization and is often associated with gram-negative multidrug-resistant organisms (MDROs). Clinicians overuse extended-spectrum antibiotics although most patients...
3.
Kramer J, Borum C, Claxon E, Wines K, Fraker S, Burgess L
J Healthc Manag
. 2023 Sep;
68(5):312-324.
PMID: 37678824
Goal: The purpose of this quality improvement project was to retrospectively evaluate pharmacist time to clinical surveillance alert intervention before and after implementing a pharmacy-directed alert priority category across a...
4.
Burgess L, Braithwaite J, Singleton E, Young A, Cooper M
HCA Healthc J Med
. 2023 Jul;
1(6):463-474.
PMID: 37427049
Description The world is in the midst of a pandemic from COVID-19, a disease caused by the virus SARS-CoV-2. Despite broad mitigation efforts, new cases continue with 74 million cases...
5.
Burgess L, Kramer J, Moran B, Cooper M, Dunn C, Murray E, et al.
HCA Healthc J Med
. 2023 Jul;
1:325-334.
PMID: 37426851
Description Planning for resumption of patient care services during and following the impact of novel coronavirus disease-2019 (COVID-19) while controlling costs are essential for pharmacy services resiliency. Implementation of a...
6.
Cooper M, Burgess L, Miller K, Baltz T, Moody J, Wiggins E, et al.
HCA Healthc J Med
. 2023 Jul;
1:419-424.
PMID: 37426842
Background: The ideal practice for patients requiring metered-dose inhalers (MDI) with coronavirus disease 2019 (COVID-19) is to use patient specific MDIs. However, this practice may not be possible during a...
7.
Burgess L, Castelein C, Rubio A, Cooper M
HCA Healthc J Med
. 2023 Jul;
2(2):81-91.
PMID: 37425646
Description Over a year has passed since the discovery of SARS-CoV-2 and the subsequent COVID-19 pandemic. As mitigation efforts continue, COVID-19 has claimed over half a million lives in the...
8.
Burgess L, Fletcher S, Cooper M, Wiggins E, Horton S, Kramer J
HCA Healthc J Med
. 2023 Jul;
2(5):367-378.
PMID: 37425133
Objective: To identify characteristics that contribute to and promote a pharmacy services center of excellence model in a large health system. Methods: In 2019, a survey was conducted of 161...
9.
Wiggins E, Kramer J, Burgess L, Warren C
HCA Healthc J Med
. 2023 Jul;
4(2):111-117.
PMID: 37424983
Background: Outcomes-directed pharmacy models are necessary to further comprehensive, patient-centric clinical care. This report describes the implementation of clinical surveillance technology and the development of clinical pharmacy metrics to measure...
10.
Wiggins E, Burgess L, Kramer J
HCA Healthc J Med
. 2023 Jul;
4(2):125-137.
PMID: 37424981
Background: Ensuring the appropriate use of proton pump inhibitors (PPIs) and histamine type 2-receptor antagonists (H2RAs) is an important hospital patient safety and quality initiative because therapy may be inappropriately...